scholarly journals Molecular insights into the OGG1 gene, a cancer risk modifier in BRCA1 and BRCA2 mutations carriers

Oncotarget ◽  
2016 ◽  
Vol 7 (18) ◽  
pp. 25815-25825 ◽  
Author(s):  
Carlos Benitez-Buelga ◽  
Tereza Vaclová ◽  
Sofia Ferreira ◽  
Miguel Urioste ◽  
Lucia Inglada-Perez ◽  
...  
Keyword(s):  
Cancer Risk ◽  
Brca1 And Brca2 ◽  
Ogg1 Gene ◽  
Brca2 Mutations ◽  
Risk Modifier ◽  
Brca1 And Brca2 Mutations

Abstract 2547: Molecular insights into OGG1 gene, a modifier of cancer risk in BRCA1 and BRCA2 mutations carriers

2016 ◽  
Author(s):  
Carlos Benitez-Buelga ◽  
Tereza Vaclova ◽  
María Sofia Ferreira ◽  
Nora Soberon ◽  
María Antonia Blasco ◽  
...  
Keyword(s):  
Cancer Risk ◽  
Brca1 And Brca2 ◽  
Ogg1 Gene ◽  
Brca2 Mutations ◽  
Brca1 And Brca2 Mutations

scholarly journals Breast Cancer Risk for Noncarriers of Family-Specific BRCA1 and BRCA2 Mutations: Findings From the Breast Cancer Family Registry

2011 ◽  
Vol 29 (34) ◽  
pp. 4505-4509 ◽  
Author(s):  
Allison W. Kurian ◽  
Gail D. Gong ◽  
Esther M. John ◽  
David A. Johnston ◽  
Anna Felberg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Brca2 Mutation ◽  
Population Based ◽  
Brca1 And Brca2 ◽  
Breast Cancer Family ◽  
Cancer Family ◽  
Brca2 Mutations ◽  
Brca1 And Brca2 Mutations

Purpose Women with germline BRCA1 and BRCA2 mutations have five- to 20-fold increased risks of developing breast and ovarian cancer. A recent study claimed that women testing negative for their family-specific BRCA1 or BRCA2 mutation (noncarriers) have a five-fold increased risk of breast cancer. We estimated breast cancer risks for noncarriers by using a population-based sample of patients with breast cancer and their female first-degree relatives (FDRs). Patients and Methods Patients were women with breast cancer and their FDRs enrolled in the population-based component of the Breast Cancer Family Registry; patients with breast cancer were tested for BRCA1 and BRCA2 mutations, as were FDRs of identified mutation carriers. We used segregation analysis to fit a model that accommodates familial correlation in breast cancer risk due to unobserved shared risk factors. Results We studied 3,047 families; 160 had BRCA1 and 132 had BRCA2 mutations. There was no evidence of increased breast cancer risk for noncarriers of identified mutations compared with FDRs from families without BRCA1 or BRCA2 mutations: relative risk was 0.39 (95% CI, 0.04 to 3.81). Residual breast cancer correlation within families was strong, suggesting substantial risk heterogeneity in women without BRCA1 or BRCA2 mutations, with some 3.4% of them accounting for roughly one third of breast cancer cases. Conclusion These results support the practice of advising noncarriers that they do not have any increase in breast cancer risk attributable to the family-specific BRCA1 or BRCA2 mutation.

BRCA1 and BRCA2 Mutation Frequency in Women Evaluated in a Breast Cancer Risk Evaluation Clinic

2002 ◽  
Vol 20 (4) ◽  
pp. 994-999 ◽  
Author(s):  
Helen A. Shih ◽  
Fergus J. Couch ◽  
Katherine L. Nathanson ◽  
M. Anne Blackwood ◽  
Timothy R. Rebbeck ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Risk Evaluation ◽  
Brca2 Mutation ◽  
Brca1 And Brca2 ◽  
Brca1 Mutations ◽  
Brca2 Mutations ◽  
Brca1 And Brca2 Mutations

PURPOSE: To determine the prevalence of BRCA1 and BRCA2 mutations in families identified in a breast cancer risk evaluation clinic. PATIENTS AND METHODS: One hundred sixty-four families seeking breast cancer risk evaluation were screened for coding region mutations in BRCA1 and BRCA2 by conformation-sensitive gel electrophoresis and DNA sequencing. RESULTS: Mutations were identified in 37 families (22.6%); 28 (17.1%) had BRCA1 mutations and nine (5.5%) had BRCA2 mutations. The Ashkenazi Jewish founder mutations 185delAG and 5382insC (BRCA1) were found in 10 families (6.1%). However, 6174delT (BRCA2) was found in only one family (0.6%) despite estimates of equal frequency in the Ashkenazi population. In contrast to other series, the average age of breast cancer diagnosis was earlier in BRCA2 mutation carriers (32.1 years) than in women with BRCA1 mutations (37.6 years, P = .028). BRCA1 mutations were detected in 20 (45.5%) of 44 families with ovarian cancer and 12 (75%) of 16 families with both breast and ovarian cancer in a single individual. Significantly fewer BRCA2 mutations (two [4.5%] of 44) were detected in families with ovarian cancer (P = .01). Eight families had male breast cancer; one had a BRCA1 mutation and three had BRCA2 mutations. CONCLUSION: BRCA1 mutations were three times more prevalent than BRCA2 mutations. Breast cancer diagnosis before 50 years of age, ovarian cancer, breast and ovarian cancer in a single individual, and male breast cancer were all significantly more common in families with BRCA1 and BRCA2 mutations, but none of these factors distinguished between BRCA1 and BRCA2 mutations. Evidence for reduced breast cancer penetrance associated with the BRCA2 mutation 6174delT was noted.

The association of BRCA1 and BRCA2 mutations on prostate cancer risk, frequency, and mortality: Systematic review and meta-analysis.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 5060-5060
Author(s):  
Mok Oh ◽  
Rana Aljadeed ◽  
Nasser Mubarak Al Khushaym ◽  
Abdulhamid Althagafi ◽  
Saad Fallatah ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Cancer Risk ◽  
Meta Analysis ◽  
Prostate Cancer Risk ◽  
Brca1 And Brca2 ◽  
Brca2 Mutations ◽  
Brca1 And Brca2 Mutations

Cancer risk management in Tasmanian women with BRCA1 and BRCA2 mutations

2017 ◽  
Vol 17 (3) ◽  
pp. 333-344 ◽  
Author(s):  
Stephanie Kearton ◽  
Karen Wills ◽  
Michael Bunting ◽  
Penny Blomfield ◽  
Paul A. James ◽  
...  
Keyword(s):  
Risk Management ◽  
Cancer Risk ◽  
Brca1 And Brca2 ◽  
Brca2 Mutations ◽  
Brca1 And Brca2 Mutations ◽  
Cancer Risk Management
Sign in / Sign up

Export Citation Format

Share Document